Home
Resources
Publications
PUGNAc Treatment Provokes Globotetraosylceramide Accumulation in Human Umbilical Vein Endothelial Cells

PUGNAc Treatment Provokes Globotetraosylceramide Accumulation in Human Umbilical Vein Endothelial Cells

Tetsuya Okuda

Biochem Biophys Res Commun. 2017 May 20;487(1):76-82.

PMID: 28392398

Abstract:

PUGNAc is a well-investigated inhibitor for protein-O-GlcNAcase, whereas recent investigations showed that PUGNAc had a broad range as inhibitor for cellular β-hexosaminidases. Here we report that PUGNAc treatment provokes globotetraosylceramide (Gb4Cer) accumulation in human umbilical vein endothelial cells (HUVEC). HPLC analysis and a quantitative ELISA using newly developed anti-Gb4Cer monoclonal antibody revealed that PUGNAc treatment specifically increased the expression of Gb4Cer among glycosphingolipids expressed in HUVEC. Although the effect was weaker than PUGNAc, an O-GlcNAcase selective inhibitor (Thiamet-G) treatment also increased Gb4Cer levels in HUVEC. Furthermore, both of PUGNAc and Thiamet-G treatment up-regulated the expression levels of α-1,4-galactosyltransferase/Gb3Cer synthase gene which encodes a key enzyme in Gb4Cer synthesis. These results indicate that protein-O-GlcNAcylation can regulate the expression levels of cellular Gb4Cer.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP132489691	PUGNAc		132489-69-1	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: